Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 4:11 pm Sale |
2022-12-31 | 13G | TScan Therapeutics, Inc. TCRX |
HILLHOUSE INVESTMENT MANAGEMENT LTD. | 0 0.000% |
-1,282,976 (Position Closed) |
Filing History |
| 2023-02-03 4:27 pm Purchase |
2022-12-31 | 13G | TScan Therapeutics, Inc. TCRX |
BLACKROCK INC BLK |
1,513,946 8.000% |
15,408 (+1.03%) |
Filing History |
| 2022-09-30 5:21 pm Purchase |
2022-09-09 | 13G | TScan Therapeutics, Inc. TCRX |
K2 HealthVentures Equity Trust LLC | 2,099,809 9.985% |
2,099,809 (New Position) |
Filing History |
| 2022-08-15 5:10 pm Sale |
2022-08-15 | 13G | TScan Therapeutics, Inc. TCRX |
RA Capital Management, L.P. | 0 0.000% |
-1,255,317 (Position Closed) |
Filing History |
| 2022-05-12 4:45 pm Purchase |
2022-05-10 | 13D | TScan Therapeutics, Inc. TCRX |
Baker Bros. Advisors LP | 2,784,792 14.700% |
1,359,792 (+95.42%) |
Filing History |
| 2022-02-14 5:24 pm Purchase |
2021-12-31 | 13G | TScan Therapeutics, Inc. TCRX |
Bessemer Venture Partners IX L.P. | 1,245,505 6.700% |
1,245,505 (New Position) |
Filing History |
| 2022-02-14 4:03 pm Purchase |
2021-12-31 | 13G | TScan Therapeutics, Inc. TCRX |
HILLHOUSE INVESTMENT MANAGEMENT LTD. | 1,282,976 6.900% |
1,282,976 (New Position) |
Filing History |
| 2022-02-14 11:39 am Purchase |
2021-12-31 | 13G | TScan Therapeutics, Inc. TCRX |
GV 2017, L.P. | 1,077,080 5.780% |
1,077,080 (New Position) |
Filing History |
| 2022-02-14 09:38 am Purchase |
2021-12-31 | 13G | TScan Therapeutics, Inc. TCRX |
Pitango HealthTech Fund I L.P. | 1,079,985 4.600% |
1,079,985 (New Position) |
Filing History |
| 2022-02-10 5:25 pm Purchase |
2021-12-31 | 13G | TScan Therapeutics, Inc. TCRX |
Longwood Fund IV L.P. | 2,315,423 12.400% |
2,315,423 (New Position) |
Filing History |
| 2022-02-04 4:12 pm Purchase |
2021-12-31 | 13G | TScan Therapeutics, Inc. TCRX |
BLACKROCK INC BLK |
1,498,538 8.000% |
1,498,538 (New Position) |
Filing History |
| 2021-07-28 4:30 pm Purchase |
2021-07-20 | 13G | TScan Therapeutics, Inc. TCRX |
RA Capital Management, L.P. | 1,255,317 6.700% |
1,255,317 (New Position) |
Filing History |
| 2021-07-22 4:20 pm Purchase |
2021-07-20 | 13D | TScan Therapeutics, Inc. TCRX |
Baker Bros. Advisors LP | 1,425,000 7.600% |
1,425,000 (New Position) |
Filing History |